 |
|
| Polypeptide and protein drugs by recombination
technology improved the availability in their therapeutic
uses. Unfortunately, short plasma half-life, low stability
to proteolytic digestion and immunological side effects
by frequent administration limited their clinical use.
|
|
| Development of therapeutic drugs by DDS
technology that improves the efficacy and reduces the
side effects of drugs has been growing rapidly worldwide
due to relatively short period of time and cost of 20-30
% compared to development of new drugs. |
|
| BPM aims to develop the second generation
of pharmaceutical products using new biocompatible PEG
derivatives by proprietary technology. |
 |
|
| 1) Development of the second generation
bioproduct conjugated to biocompatible polymers → Interferon,
G-CSF, PTH, EPO, Human Growth Hormone, IL-2, SCA,etc. |
|
| 2) Development of PEG derivatives to increase
the bioavailability of drugs by enhancing cell trafficking
and specific organ targeting → Anticancer agents, anti-virus
agents
|
|
3) Development of highly effective siRNA delivery system
→ chitosan based polymer carriers
→ lipid based carriers
|
